Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

  1. De Santis, M.
  2. Breijo, S.M.
  3. Robinson, P.
  4. Capone, C.
  5. Pascoe, K.
  6. Van Sanden, S.
  7. Hashim, M.
  8. Trevisan, M.
  9. Daly, C.
  10. Reitsma, F.
  11. van Beekhuizen, S.
  12. Ruan, H.
  13. Heeg, B.
  14. Verzoni, E.
Revista:
Advances in Therapy

ISSN: 1865-8652 0741-238X

Año de publicación: 2024

Tipo: Revisión

DOI: 10.1007/S12325-024-02918-6 GOOGLE SCHOLAR lock_openAcceso abierto editor